We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.37B
AUM Growth
+$301M
Cap. Flow
+$225M
Cap. Flow %
16.4%
Top 10 Hldgs %
27.24%
Holding
130
New
25
Increased
53
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$31.4M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$15.5M
3
COLL icon
Collegium Pharmaceutical
COLL
+$13M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.6M
5
ACHC icon
Acadia Healthcare
ACHC
+$10.7M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$22.5M
2
SRCL
Stericycle Inc
SRCL
+$10.3M
3
LH icon
Labcorp
LH
+$9.46M
4
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$7.97M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 76.77%
2 Financials 1.46%
3 Technology 0.96%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSLT
76
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$6.51M 0.48%
800,000
+275,000
+52% +$2.29M
TBPH icon
77
Theravance Biopharma
TBPH
$877M
$6.18M 0.45%
475,000
+101,000
+27% +$1.57M
ASMB icon
78
Assembly Biosciences
ASMB
$529M
$6.04M 0.44%
26,125
-333
-1% -$64.3K
NVTA
79
DELISTED
Invitae Corporation
NVTA
$5.95M 0.43%
400,000
+275,000
+220% +$3.91M
CORV
80
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$5.88M 0.43%
625,000
+60,000
+11% +$559K
TNDM icon
81
Tandem Diabetes Care
TNDM
$1.56B
$5.8M 0.42%
53,500
+5,920
+12% +$736K
REGN icon
82
Regeneron Pharmaceuticals
REGN
$80.8B
$5.61M 0.41%
11,000
+1,000
+10% +$488K
FOLD
83
DELISTED
Amicus Therapeutics
FOLD
$5.34M 0.39%
+377,500
New +$4.54M
INSY
84
DELISTED
Insys Therapeutics, Inc.
INSY
$5.28M 0.39%
+147,000
New +$4.58M
AGN.PRA
85
DELISTED
Allergan plc
AGN.PRA
$5.23M 0.38%
+5,000
New +$5.23M
MGNX icon
86
MacroGenics
MGNX
$257M
$5.22M 0.38%
137,500
+21,000
+18% +$690K
CO
87
DELISTED
Global Cord Blood Corporation
CO
$5.11M 0.37%
830,000
– –
WCG
88
DELISTED
Wellcare Health Plans, Inc.
WCG
$5.09M 0.37%
60,000
– –
XENT
89
DELISTED
Intersect ENT, Inc
XENT
$5.01M 0.37%
+175,000
New +$4.59M
CERN
90
DELISTED
Cerner Corp
CERN
$4.83M 0.35%
70,000
+10,000
+17% +$700K
RPTP
91
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$4.82M 0.35%
305,000
+150,000
+97% +$1.82M
PCRX icon
92
Pacira BioSciences
PCRX
$997M
$4.81M 0.35%
68,000
+17,250
+34% +$1.36M
JAZZ icon
93
Jazz Pharmaceuticals
JAZZ
$16.7B
$4.58M 0.33%
26,000
– –
PETX
94
DELISTED
Aratana Therapeutics, Inc.
PETX
$4.54M 0.33%
+300,000
New +$4.33M
KYNB
95
Kyntra Bio
KYNB
$29.4M
$4.46M 0.33%
7,600
+1,548
+26% +$900K
BMRN icon
96
BioMarin Pharmaceuticals
BMRN
$12.4B
$4.45M 0.32%
32,500
– –
DERM
97
DELISTED
Dermira, Inc.
DERM
$4.39M 0.32%
250,001
+207,727
+491% +$3.2M
ATHN
98
DELISTED
Athenahealth, Inc.
ATHN
$4.35M 0.32%
+38,000
New +$4.54M
ASND icon
99
Ascendis Pharma A/S
ASND
$16.8B
$4.24M 0.31%
240,000
+204,460
+575% +$3.58M
ALBO
100
DELISTED
Albireo Pharma Inc
ALBO
$4.12M 0.3%
+133,333
New +$4.48M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rock Springs Capital Management held 130 positions worth $1.37B, up 28% from $1.07B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $225M of net new capital in Q2 2015, opening 25 new positions and adding to 53 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $6.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2015 buy was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.
  • Rock Springs Capital Management added most to Spark Therapeutics, Inc. Common Stock in Q2 2015, an estimated $31.4M increase.
  • Rock Springs Capital Management's biggest Q2 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $6.9M.
  • Rock Springs Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $22.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.37B portfolio in Q2 2015.
  • Rock Springs Capital Management opened 25 new positions and closed 13 in Q2 2015.
  • Rock Springs Capital Management's portfolio value rose 28% quarter-over-quarter to $1.37B.

Based on Rock Springs Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.